,author,keywords,pmc,pmid,prob,pubdate,title
0,F Huang; A Ajavon; E Huang; J Lettieri; R Liu; C Peña; M Berse,clinical research; clinical trials; thyroid cancer — clinical,,28741453,0.9987810254096985,2017,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
1,A Awada; A Hendlisz; O Christensen; CD Lathia; S Bartholomeus; F Lebrun; D de Valeriola; E Brendel; M Radtke; T Delaunoit; M Piccart-Gebhart; T Gil,,,22285181,0.9975842237472534,2012,"Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours."
2,KGAM Hussaarts; L van Doorn; K Eechoute; J Damman; Q Fu; N van Doorn; ED Eisenmann; AA Gibson; E Oomen-de Hoop; P de Bruijn; SD Baker; SLW Koolen; T van Gelder; RWF van Leeuwen; RHJ Mathijssen; A Sparreboom; S Bins,OAT6; hand-foot skin reaction (HFSR); pharmacokinetics; probenecid; sorafenib,,32825359,0.9974600672721863,2020,Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.
3,AA Adjei; DA Richards; A El-Khoueiry; F Braiteh; CH Becerra; JJ Stephenson; AF Hezel; M Sherman; L Garbo; DP Leffingwell; C Iverson; JN Miner; Z Shen; LT Yeh; S Gunawan; DM Wilson; KJ Manhard; P Rajagopalan; H Krissel; NJ Clendeninn,,,26644411,0.9974130988121033,2016,"A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer."
4,H Akaza; T Tsukamoto; M Murai; K Nakajima; S Naito,,,17951335,0.9970589876174927,2007,"Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma."
5,DH Palmer; YT Ma; M Peck-Radosavljevic; P Ross; J Graham; L Fartoux; A Deptala; M Studeny; D Schnell; J Hocke; AB Loembé; T Meyer,,,29563636,0.997055172920227,2018,"A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma."
6,AA Miller; DJ Murry; K Owzar; DR Hollis; EB Kennedy; G Abou-Alfa; A Desai; J Hwang; MA Villalona-Calero; EC Dees; LD Lewis; MG Fakih; MJ Edelman; F Millard; RC Frank; RJ Hohl; MJ Ratain,,,19255312,0.9969122409820557,2009,Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
7,M Moore; HW Hirte; L Siu; A Oza; SJ Hotte; O Petrenciuc; F Cihon; C Lathia; B Schwartz,,,16006586,0.9968532919883728,2005,"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors."
8,A Kim; C McCully; R Cruz; DE Cole; E Fox; FM Balis; BC Widemann,,,21072558,0.996711015701294,2012,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
9,RK Kelley; HS Nimeiri; PN Munster; MT Vergo; Y Huang; CM Li; J Hwang; MF Mulcahy; BM Yeh; P Kuhn; MS Luttgen; JA Grabowsky; L Stucky-Marshall; WM Korn; AH Ko; EK Bergsland; AB Benson; AP Venook,hepatocellular carcinoma; mTOR; pharmacokinetics; sorafenib; temsirolimus,,23519998,0.9966553449630737,2013,Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
10,A Awada; A Hendlisz; T Gil; S Bartholomeus; M Mano; D de Valeriola; D Strumberg; E Brendel; CG Haase; B Schwartz; M Piccart,,,15870716,0.9964699745178223,2005,"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours."
11,T Okusaka; T Aramaki; Y Inaba; S Nakamura; M Morimoto; M Moriguchi; T Sato; Y Ikawa; M Ikeda; J Furuse,CYP2C19 polymorphisms; c-Met inhibitor; hepatocellular carcinoma; phase I study; tivantinib,,25711511,0.9960131645202637,2015,Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
12,X Wang; X Zhang; F Liu; M Wang; S Qin,CYP3A4; P-gp; herb–drug interaction,,28614959,0.9958048462867737,2017,The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
13,A Awada; T Gil; N Whenham; J Van Hamme; T Besse-Hammer; E Brendel; H Delesen; MC Joosten; CD Lathia; BA Loembé; M Piccart-Ghebart; A Hendlisz,,,21209247,0.9955254197120667,2011,Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
14,E Brendel; M Ludwig; C Lathia; C Robert; S Ropert; JC Soria; JP Armand,,,20821331,0.9952327609062195,2011,Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
15,JW Clark; JP Eder; D Ryan; C Lathia; HJ Lenz,,,16061863,0.9948444366455078,2005,"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors."
16,KT Flaherty; C Lathia; RF Frye; L Schuchter; M Redlinger; M Rosen; PJ O'Dwyer,,,21350850,0.9947808384895325,2011,Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
17,BC Widemann; A Kim; E Fox; S Baruchel; PC Adamson; AM Ingle; J Glade Bender; M Burke; B Weigel; D Stempak; FM Balis; SM Blaney,,,22962440,0.9946625828742981,2012,A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
18,I Okamoto; M Miyazaki; R Morinaga; H Kaneda; S Ueda; Y Hasegawa; T Satoh; A Kawada; M Fukuoka; K Fukino; T Tanigawa; K Nakagawa,,,19760364,0.9939024448394775,2010,Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
19,E Shacham-Shmueli; R Geva; A Figer; S Bulocinic; K Nalbandyan; S Shpigel; J Atsmon; E Brendel,,,22232731,0.9937872886657715,2012,Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
20,H Minami; K Kawada; H Ebi; K Kitagawa; YI Kim; K Araki; H Mukai; M Tahara; H Nakajima; K Nakajima,,,18477034,0.9931219220161438,2008,"Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors."
21,C Lathia; J Lettieri; F Cihon; M Gallentine; M Radtke; P Sundaresan,,,16133532,0.9926215410232544,2006,Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
22,KY Huh; S Hwang; SY Park; HJ Lim; M Jin; J Oh; KS Yu; JY Chung,bioavailability; enterohepatic reabsorption; pharmacokinetics; pharmacometrics; sorafenib,,33925058,0.9925490617752075,2021,Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib.
23,D Strumberg; H Richly; RA Hilger; N Schleucher; S Korfee; M Tewes; M Faghih; E Brendel; D Voliotis; CG Haase; B Schwartz; A Awada; R Voigtmann; ME Scheulen; S Seeber,,,15613696,0.9911688566207886,2005,Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
24,A Karbownik; D Szkutnik-Fiedler; A Czyrski; N Kostewicz; P Kaczmarska; M Bekier; J Stanisławiak-Rudowicz; M Karaźniewicz-Łada; A Wolc; F Główka; E Grześkowiak; E Szałek,atorvastatin; drug–drug interaction; metformin; pharmacokinetics; sorafenib; sorafenib N-oxide,,32605304,0.9911496639251709,2020,"Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats."
25,M Simonelli; PA Zucali; E Lorenzi; L Rubino; F De Vincenzo; R De Sanctis; M Perrino; L Mancini; L Di Tommaso; L Rimassa; G Masci; M Zuradelli; MB Suter; M Bertossi; G Fattuzzo; L Giordano; MG Roncalli; A Santoro,,,23146956,0.9905335903167725,2013,Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
26,M Hornecker; B Blanchet; B Billemont; H Sassi; S Ropert; F Taieb; O Mir; H Abbas; L Harcouet; R Coriat; A Dauphin; F Goldwasser; M Tod,,,22006162,0.9900254011154175,2012,Saturable absorption of sorafenib in patients with solid tumors: a population model.
27,HM Maher; A Almomen; NZ Alzoman; SM Shehata; A Al-Subaie,,,31871933,0.9890003204345703,2019,A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction.
28,AW Tolcher; LJ Appleman; GI Shapiro; AC Mita; F Cihon; A Mazzu; PR Sundaresan,,,20521052,0.987586259841919,2011,A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
29,H Inaba; JE Rubnitz; E Coustan-Smith; L Li; BD Furmanski; GP Mascara; KM Heym; R Christensen; M Onciu; SA Shurtleff; SB Pounds; CH Pui; RC Ribeiro; D Campana; SD Baker,,,21768474,0.9870607852935791,2011,Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
30,X Luo; S Li; Y Xie; J He; J Li; H Lin; N Wang; S Yang; Y Zhao; L Yu; X Song,,,22710664,0.9867860674858093,2013,Pharmacokinetic studies of a novel multikinase inhibitor for treating cancer by HPLC-UV.
31,L Goyal; RC Wadlow; LS Blaszkowsky; BM Wolpin; TA Abrams; NJ McCleary; S Sheehan; E Sundaram; MD Karol; J Chen; AX Zhu,,,25248753,0.9859433174133301,2015,A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
32,HJ Meany; BC Widemann; PS Hinds; R Bagatell; S Shusterman; E Stern; N Jayaprakash; CJ Peer; WD Figg; OM Hall; TM Sissung; A Kim; E Fox; WB London; C Rodriguez-Galindo; JE Minturn; JS Dome,irinotecan; pediatric; phase 1; solid tumors; sorafenib,,34383370,0.9857912063598633,2021,Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
33,JJ Harding; RK Kelley; B Tan; M Capanu; GK Do; J Shia; JF Chou; CS Ferrer; C Boussayoud; K Muenkel; H Yarmohammadi; I El Dika; DN Khalil; C Ruiz; M Rodriguez-Lee; P Kuhn; J Wilton; R Iyer; GK Abou-Alfa,,,32548867,0.9856465458869934,2020,Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
34,T Kennoki; T Kondo; N Kimata; J Murakami; I Ishimori; H Nakazawa; Y Hashimoto; H Kobayashi; J Iizuka; T Takagi; K Yoshida; K Tanabe,,,21367805,0.9852796792984009,2011,Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
35,N Azad; A Dasari; J Arcaroli; GE Taylor; DA Laheru; MA Carducci; M McManus; K Quackenbush; JJ Wright; M Hidalgo; LA Diaz; RC Donehower; M Zhao; MA Rudek; WA Messersmith,,,22615057,0.9846835732460022,2013,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer."
36,S Loibl; D Rokitta; B Conrad; N Harbeck; M Wüllner; M Warm; K Schwedler; B Gerber; I Schrader; H Eidtmann; K Mehta; U Fuhr; G von Minckwitz,Anthracycline; Breast cancer; Pharmacokinetics; Sorafenib; Taxane,,25177258,0.9842860102653503,2014,Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.
37,LS Rosen; I Puzanov; G Friberg; E Chan; YC Hwang; H Deng; J Gilbert; D Mahalingam; I McCaffery; SA Michael; AC Mita; MM Mita; M Mulay; P Shubhakar; M Zhu; J Sarantopoulos,,,22510349,0.9842533469200134,2012,"Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors."
38,M Ikeda; M Morimoto; M Tajimi; K Inoue; KA Benhadji; MMF Lahn; D Sakai,Galunisertib; Hepatocellular carcinoma; Japan; Phase I clinical trial; Sorafenib,,29995286,0.9838823080062866,2019,A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
39,LB Nabors; JG Supko; M Rosenfeld; M Chamberlain; S Phuphanich; T Batchelor; S Desideri; X Ye; J Wright; S Gujar; SA Grossman; ,,,21954442,0.9831148982048035,2011,Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
40,J Furuse; H Ishii; K Nakachi; E Suzuki; S Shimizu; K Nakajima,,,17953709,0.9823707342147827,2008,Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
41,CT Ting; YY Cheng; TH Tsai,,,33553923,0.9822186827659607,2021,Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats.
42,NJ Koehl; R Holm; M Kuentz; BT Griffin,brick dust molecule; chase dosing; lipid based formulation; lipid suspension; poorly water-soluble drugs,,32524365,0.9818857312202454,2020,Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats.
43,J Arrondeau; O Mir; P Boudou-Rouquette; R Coriat; S Ropert; G Dumas; MJ Rodrigues; B Rousseau; B Blanchet; F Goldwasser,,,22038662,0.9814127683639526,2012,Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
44,GK Abou-Alfa; SL Chan; CC Lin; EG Chiorean; RF Holcombe; MF Mulcahy; WD Carter; K Patel; WR Wilson; TJ Melink; JC Gutheil; CJ Tsao,,,21594722,0.9809548854827881,2011,PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
45,A Karbownik; J Stanisławiak-Rudowicz; A Stachowiak; M Romański; E Grześkowiak; E Szałek,,,32776310,0.9806744456291199,2020,The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood-Brain Barrier in Rats.
46,K Wang; FS Stark; T Schlothauer; A Lahr; V Cosson; J Zhi; K Habben; J Tessier; E Schick; RF Staack; O Krieter,Bevacizumab; Drug interactions; Pharmacokinetics; Placenta growth factor; RO5323441; Vascular endothelial growth factor receptor,,28314990,0.9786697626113892,2017,An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.
47,S Noda; M Shioya; D Hira; Y Fujiyama; SY Morita; T Terada,,,23673446,0.9778538346290588,2013,Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
48,H Zhang; FM Zhang; SJ Yan,HPLC; material phase analysis; pharmacokinetics; release profile; solid lipid nanoparticles; sorafenib,,22787390,0.9775766730308533,2012,"Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles."
49,H Inaba; JC Panetta; SB Pounds; L Wang; L Li; F Navid; SM Federico; ED Eisenmann; A Vasilyeva; YD Wang; S Shurtleff; CH Pui; TA Gruber; RC Ribeiro; JE Rubnitz; SD Baker,,,31455680,0.9774456024169922,2019,Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.
50,DM Peereboom; MS Ahluwalia; X Ye; JG Supko; SL Hilderbrand; S Phuphanich; LB Nabors; MR Rosenfeld; T Mikkelsen; SA Grossman; ,,,23328813,0.9769688248634338,2013,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
51,J Liu; X Li; H Zhang; G Chen; H Chen; Y Hu; J Niu; Y Ding,,,31739839,0.9768643975257874,2019,"Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial."
52,C Liu; Z Chen; Y Chen; J Lu; Y Li; S Wang; G Wu; F Qian,bioavailability; molecular interaction; polymer−surfactant complex; poorly water-soluble drugs; sorafenib,,26709621,0.9757066965103149,2016,"Improving Oral Bioavailability of Sorafenib by Optimizing the ""Spring"" and ""Parachute"" Based on Molecular Interaction Mechanisms."
53,KT Flaherty; J Schiller; LM Schuchter; G Liu; DA Tuveson; M Redlinger; C Lathia; C Xia; O Petrenciuc; SR Hingorani; MA Jacobetz; PA Van Belle; D Elder; MS Brose; BL Weber; MR Albertini; PJ O'Dwyer,,,18676756,0.975073516368866,2008,"A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel."
54,TA Labeur; Q Hofsink; RB Takkenberg; OM van Delden; RAA Mathôt; R Schinner; P Malfertheiner; H Amthauer; K Schütte; B Basu; C Kuhl; J Mayerle; J Ricke; HJ Klümpen,hepatocellular carcinoma; pharmacokinetics; sorafenib; survival; toxicity,,32366155,0.9750176072120667,2020,The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial.
55,DS Hong; MS Gordon; WE Samlowski; R Kurzrock; N Tannir; D Friedland; DS Mendelson; NJ Vogelzang; E Rasmussen; BM Wu; MB Bass; ZD Zhong; G Friberg; LJ Appleman,Angiogenesis; Angiopoietins; Targeted therapies; Tie2 receptor; Vascular growth factor receptor,,24365125,0.9744648933410645,2014,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma."
56,T Isobe; R Komatsu; M Honda; S Kuramoto; H Shindoh; M Tabo,,,24646704,0.9741790294647217,2014,Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
57,RK Kelley; E Gane; E Assenat; J Siebler; PR Galle; P Merle; IO Hourmand; A Cleverly; Y Zhao; I Gueorguieva; M Lahn; S Faivre; KA Benhadji; G Giannelli,,,31295152,0.9741306304931641,2019,A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
58,AF Hottinger; A Ben Aissa; V Espeli; D Squiban; N Dunkel; MI Vargas; T Hundsberger; N Mach; K Schaller; DC Weber; A Bodmer; PY Dietrich,,,24786603,0.9718983173370361,2014,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
59,N Pécuchet; C Lebbe; O Mir; B Billemont; B Blanchet; N Franck; M Viguier; R Coriat; M Tod; MF Avril; F Goldwasser,,,22767146,0.9718247056007385,2012,Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
60,D Paul; P Chandrakala; S Surendran; P Bitla; N Satheeshkumar,Hepatocellular carcinoma; Palbociclib; Pharmacokinetic-interaction study; Sorafenib,,30660839,0.9706684350967407,2019,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats.
61,A Parvinian; LC Casadaban; ZZ Hauck; RB van Breemen; RC Gaba,,,25835078,0.9704528450965881,2015,Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
62,CJ Peer; TM Sissung; A Kim; L Jain; S Woo; ER Gardner; CT Kirkland; SM Troutman; BC English; ED Richardson; J Federspiel; D Venzon; W Dahut; E Kohn; S Kummar; R Yarchoan; G Giaccone; B Widemann; WD Figg,,,22307138,0.9703558683395386,2012,Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
63,Y He; L Zhou; S Gao; T Yin; Y Tu; R Rayford; X Wang; M Hu,Mice pharmacokinetics; Tyrosine kinase inhibitors; UHPLC–MS/MS,,28965046,0.9701550006866455,2018,Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies.
64,J Martín-Liberal; A López-Pousa; JM Broto; R Cubedo; O Gallego; E Brendel; OM Tirado; XG del Muro,,,23801301,0.968848466873169,2014,Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
65,XQ Wang; JM Fan; YO Liu; B Zhao; ZR Jia; Q Zhang,,,21843612,0.9687163829803467,2011,"Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat."
66,C Nabhan; D Villines; TV Valdez; K Tolzien; TM Lestingi; JD Bitran; SM Christner; MJ Egorin; JH Beumer,,,22805325,0.9665570855140686,2012,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
67,Y Shi; Z Zhao; Y Gao; DC Pan; AK Salinas; EEL Tanner; J Guo; S Mitragotri,Biodistribution; Ionic liquids; Oral absorption; Sorafenib; UPLC-MS,,32201308,0.9658884406089783,2020,Oral delivery of sorafenib through spontaneous formation of ionic liquid nanocomplexes.
68,UN Vaishampayan; AM Burger; EA Sausville; LK Heilbrun; J Li; MN Horiba; MJ Egorin; P Ivy; S Pacey; PM Lorusso,,,20525756,0.9631696939468384,2010,"Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin."
69,C Gomo; R Coriat; L Faivre; O Mir; S Ropert; B Billemont; A Dauphin; M Tod; F Goldwasser; B Blanchet,,,20706860,0.9628493189811707,2011,Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
70,AA Adjei; JR Molina; SJ Mandrekar; R Marks; JR Reid; G Croghan; LJ Hanson; JR Jett; C Xia; C Lathia; R Simantov,,,17473200,0.9596644043922424,2007,Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
71,JR Infante; SF Jones; JC Bendell; FA Greco; DA Yardley; CM Lane; DR Spigel; JD Hainsworth; HA Burris,,,21626051,0.9592959880828857,2012,A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
72,T Ishii; E Hatano; K Taura; T Mizuno; T Kawai; M Fukudo; T Katsura; S Uemoto,hemodialysis; hepatocellular carcinoma; renal failure; sorafenib,,23639221,0.9586535692214966,2014,Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study.
73,DR Reed; L Mascarenhas; K Manning; GA Hale; J Goldberg; J Gill; E Sandler; MS Isakoff; T Smith; J Caracciolo; RM Lush; TH Juan; JK Lee; AM Neuger; DM Sullivan,Combination; pediatric cancer; phase I; sarcoma; sorafenib; topotecan,,26714427,0.9546576142311096,2016,Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
74,MJ Gnoth; S Sandmann; K Engel; M Radtke,,,20413726,0.953199565410614,2010,In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
75,I Duran; SJ Hotté; H Hirte; EX Chen; M MacLean; S Turner; L Duan; GR Pond; C Lathia; S Walsh; JJ Wright; J Dancey; LL Siu,,,17699864,0.9501234889030457,2007,Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
76,B Escudier; N Lassau; E Angevin; JC Soria; L Chami; M Lamuraglia; E Zafarana; V Landreau; B Schwartz; E Brendel; JP Armand; C Robert,,,17363536,0.9490283727645874,2007,Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
77,CT Ting; YY Cheng; TH Tsai,Chinese herbal medicine; Radix Gentianae formulation; hepatocellular carcinoma; pharmacokinetics; sorafenib,,28640225,0.9482958316802979,2017,"Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats."
78,L Jain; S Woo; ER Gardner; WL Dahut; EC Kohn; S Kummar; DR Mould; G Giaccone; R Yarchoan; J Venitz; WD Figg,,,21392074,0.9455946087837219,2011,Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
79,Á Díaz-González; V Sapena; L Boix; M Brunet; F Torres; N LLarch; E Samper; O Millán; J Corominas; G Iserte; M Sanduzzi-Zamparelli; LG da Fonseca; A Darnell; E Belmonte; A Forner; C Ayuso; J Bruix; M Reig,Tyrosine Kinase Inhibitor; hepatocellular carcinoma; outcome; pharmacokinetics; safety; sorafenib,,33021346,0.9452587366104126,2020,Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
80,M Quintela-Fandino; C Le Tourneau; I Duran; EX Chen; L Wang; M Tsao; B Bandarchi-Chamkhaleh; NA Pham; T Do; M MacLean; R Nayyar; MW Tusche; U Metser; JJ Wright; TW Mak; LL Siu,,,20197396,0.9449512362480164,2010,"Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort."
81,RA Hilger; H Richly; M Grubert; S Kredtke; D Thyssen; W Eberhardt; J Hense; M Schuler; ME Scheulen,,,19203541,0.9444246292114258,2009,Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
82,A Kim; E Dombi; K Tepas; E Fox; S Martin; P Wolters; FM Balis; N Jayaprakash; B Turkbey; N Muradyan; PL Choyke; A Reddy; B Korf; BC Widemann,,,22961690,0.9440882205963135,2013,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
83,O Mir; R Coriat; B Blanchet; JP Durand; P Boudou-Rouquette; J Michels; S Ropert; M Vidal; S Pol; S Chaussade; F Goldwasser,,,22666367,0.9410632848739624,2012,Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
84,P Kupsch; BF Henning; K Passarge; H Richly; K Wiesemann; RA Hilger; ME Scheulen; O Christensen; E Brendel; B Schwartz; E Hofstra; R Voigtmann; S Seeber; D Strumberg,,,16197622,0.9390488862991333,2005,"Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer."
85,F Navid; SD Baker; MB McCarville; CF Stewart; CA Billups; J Wu; AM Davidoff; SL Spunt; WL Furman; LM McGregor; S Hu; JC Panetta; D Turner; D Fofana; WE Reddick; W Leung; VM Santana,,,23143218,0.938461422920227,2013,"Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors."
86,H Wang; H Wang; W Yang; M Yu; S Sun; B Xie,evaluation; liver targeting; pharmacokinetics; solid lipid nanoparticle; sorafenib,,28983849,0.9358487725257874,2018,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
87,WM Tai; WP Yong; C Lim; LS Low; CK Tham; TS Koh; QS Ng; WW Wang; LZ Wang; S Hartano; CH Thng; H Huynh; KT Lim; HC Toh; BC Goh; SP Choo,"hepatocellular carcinoma; pharmacokinetics; selumetinib (AZD6244, ARRY-142886); sorafenib",,27681866,0.9335094094276428,2016,"A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)."
88,SM Lin; SN Lu; PT Chen; LB Jeng; SC Chen; CT Hu; SS Yang; MA Le Berre; X Liu; DY Mitchell; K Prins; J Grevel; CA Peña; G Meinhardt,Advanced hepatocellular carcinoma; Metastatic hepatocellular carcinoma; Overall survival; Sorafenib; Taiwanese patients; Time to progression,,27909950,0.9293386936187744,2017,"HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma."
89,CU Phan; J Shen; K Yu; J Mao; G Tang,crystal habit; dissolution rate; pharmacokinetics; sorafenib tosylate,,34200376,0.9216135144233704,2021,Impact of Crystal Habit on the Dissolution Rate and In Vivo Pharmacokinetics of Sorafenib Tosylate.
90,SC Tang; N de Vries; RW Sparidans; E Wagenaar; JH Beijnen; AH Schinkel,,,23843632,0.9212778806686401,2013,"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib."
91,C Ferrario; I Strepponi; K Esfahani; H Charamis; A Langleben; E Scarpi; O Nanni; WH Miller; LC Panasci,,,27992451,0.919958770275116,2016,Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
92,DA Reardon; JJ Vredenburgh; A Desjardins; K Peters; S Gururangan; JH Sampson; J Marcello; JE Herndon; RE McLendon; D Janney; AH Friedman; DD Bigner; HS Friedman,,,20443129,0.9192419052124023,2011,Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
93,GK Abou-Alfa; D Amadori; A Santoro; A Figer; J De Greve; C Lathia; D Voliotis; S Anderson; M Moscovici; S Ricci,,,21673874,0.91860431432724,2011,Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.
94,SJ Lee; J Lee; SH Park; JO Park; YS Park; WK Kang; J Lee; DS Yim; HY Lim,,,21695438,0.9183651208877563,2012,Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
95,B Schultheis; G Kummer; M Zeth; E Brendel; C Xia; M Kornacker; D Strumberg,,,21735354,0.9130369424819946,2012,Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
96,Y Lou; L Wang; Q Qian; J You; W Qiu; Q Wang; K Zhu; Y Qiu,BZG; Multikinase inhibitor; Novel sorafenib analogues; Pharmacokinetics; Tissue distribution; UPLC–MS/MS,,26799978,0.90846848487854,2016,Preclinical pharmacokinetics and tissue distribution of a novel multikinase inhibitor BZG by validated UPLC-MS/MS assay.
97,MA Khan; S Ali; SS Venkatraman; MF Sohail; M Ovais; A Raza,Co-block polymer; Oral delivery; Polymersomes; Sorafenib,,29551745,0.906640350818634,2018,Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
98,M Niwakawa; K Hashine; R Yamaguchi; H Fujii; Y Hamamoto; K Fukino; T Tanigawa; Y Sumiyoshi,,,21246251,0.9066011309623718,2012,Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
99,CH Hsieh; YJ Chen; TH Tsai; LY Wang; HC Tai; HL Huang; YC Huang,,,32533042,0.9065256118774414,2020,Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters.
100,F Mardjuadi; J Medioni; J Kerger; L D'Hondt; JL Canon; L Duck; F Musuamba; S Oudard; M Clausse; A Moxhon; JP Machiels,,,22752248,0.9059994220733643,2012,Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
101,C Jiang; L Xie; Y Zhang; M Fujinaga; W Mori; Y Kurihara; T Yamasaki; F Wang; MR Zhang,BRAFV600E mutation; [11C]CEP-32496; melanoma; pharmacokinetic evaluation; positron emission tomography,,30251592,0.905269980430603,2018,Pharmacokinetic Evaluation of [11C]CEP-32496 in Nude Mice Bearing BRAFV600E Mutation-Induced Melanomas.
102,AK El-Damasy; NC Cho; G Nam; AN Pae; G Keum,anticancer activity; benzothiazoles; ethylpiperazine; multikinase inhibitors,,27405013,0.9050202965736389,2016,Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.
103,L Bazzola; C Foroni; D Andreis; V Zanoni; M R Cappelletti; G Allevi; S Aguggini; C Strina; M Milani; S Venturini; F Ferrozzi; R Giardini; R Bertoni; H Turley; K Gatter; PG Petronini; SB Fox; AL Harris; M Martinotti; A Berruti; A Bottini; AR Reynolds; D Generali,,,25461806,0.9028123021125793,2015,"Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer."
104,JW Choi; JH Park; HR Cho; JW Chung; DD Kim; HC Kim; HJ Cho,,,28373713,0.9019298553466797,2017,"Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor."
105,JC Panetta; O Campagne; J Gartrell; W Furman; CF Stewart,,,34060723,0.901069164276123,2021,Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study.
106,F Navid; R Christensen; H Inaba; L Li; Z Chen; X Cai; J Regel; SD Baker,compounded capsule; formulation; sorafenib; suspension,,23788485,0.9001465439796448,2013,Alternative formulations of sorafenib for use in children.
107,Y Chu; J Zhang; H Pan; J Shi; J Wang; L Chen,Biomimetic hybrid drug delivery system; Long circulation; RBCm-derived vesicles; Sorafenib,,32399603,0.8997125029563904,2020,Preparation and evaluation of long circulating erythrocyte membrane-cloaked anti-cancer drug delivery system.
108,Y Chen; A Suzuki; MA Tortorici; M Garrett; RR LaBadie; Y Umeyama; YK Pithavala,,,25663295,0.8993229269981384,2015,Axitinib plasma pharmacokinetics and ethnic differences.
109,A Zambon; D Ménard; BM Suijkerbuijk; I Niculescu-Duvaz; S Whittaker; D Niculescu-Duvaz; A Nourry; L Davies; HA Manne; F Lopes; N Preece; D Hedley; LM Ogilvie; R Kirk; R Marais; CJ Springer,,,20597484,0.898539662361145,2010,Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
110,K Mross; S Steinbild; F Baas; D Gmehling; M Radtke; D Voliotis; E Brendel; O Christensen; C Unger,,,17095207,0.8978002071380615,2007,Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
111,GK Abou-Alfa; L Schwartz; S Ricci; D Amadori; A Santoro; A Figer; J De Greve; JY Douillard; C Lathia; B Schwartz; I Taylor; M Moscovici; LB Saltz,,,16908937,0.8975152969360352,2006,Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
112,A Karbownik; K Sobańska; T Grabowski; J Stanisławiak-Rudowicz; A Wolc; E Grześkowiak; E Szałek,Drug–drug interaction; Paracetamol; Paracetamol glucuronide and paracetamol sulphate; Pharmacokinetics; Sorafenib; Sorafenib N-oxide,,32394097,0.8953949809074402,2020,In vivo assessment of the drug interaction between sorafenib and paracetamol in rats.
113,SY Park; Z Kang; P Thapa; YS Jin; JW Park; HJ Lim; JY Lee; SW Lee; MH Seo; MS Kim; SH Jeong,Dissolution; NUFS™; Particle size; Pharmacokinetics; Quality by design; Sorafenib,,31136778,0.8952245712280273,2019,Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach.
114,IM Desar; JN Timmer-Bonte; DM Burger; WT van der Graaf; CM van Herpen,,,21045832,0.894199013710022,2010,A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
115,T Okusaka; H Ueno; M Ikeda; S Mitsunaga; M Ozaka; H Ishii; O Yokosuka; Y Ooka; R Yoshimoto; Y Yanagihara; K Okita,OPB-31121; advanced hepatocellular carcinoma; dose escalation; phase 1 trial; recommended dose; signal transducer and activator of transcription-3 inhibitor,,25676869,0.8904064297676086,2015,"Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma."
116,SM Stemmer; O Benjaminov; G Medalia; NB Ciuraru; MH Silverman; S Bar-Yehuda; S Fishman; Z Harpaz; M Farbstein; S Cohen; R Patoka; B Singer; WD Kerns; P Fishman,,,23299770,0.8892553448677063,2013,"CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study."
117,I Puzanov; J Sosman; A Santoro; MW Saif; L Goff; GK Dy; P Zucali; JA Means-Powell; WW Ma; M Simonelli; R Martell; F Chai; M Lamar; RE Savage; B Schwartz; AA Adjei,,,25294187,0.886177659034729,2015,Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
118,H Richly; P Kupsch; K Passage; M Grubert; RA Hilger; S Kredtke; D Voliotis; ME Scheulen; S Seeber; D Strumberg,,,14692720,0.8857759237289429,2003,A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
119,TA Labeur; R Achterbergh; B Takkenberg; O Van Delden; R Mathôt; HJ Klümpen,,,31645371,0.8843458890914917,2020,Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
120,I Khan; Z Iqbal; A Khan; M Hassan; F Nasir; A Raza; L Ahmad; A Khan; M Akhlaq Mughal,Biological samples; Paclitaxel; Pharmacokinetics; RP-HPLC; Sorafenib,,27592284,0.8808923363685608,2016,"A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study."
121,LL Siu; A Awada; CH Takimoto; M Piccart; B Schwartz; T Giannaris; C Lathia; O Petrenciuc; MJ Moore,,,16397036,0.8800032138824463,2006,Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
122,L Nogova; C Mattonet; M Scheffler; M Taubert; M Gardizi; ML Sos; S Michels; RN Fischer; M Limburg; DSY Abdulla; T Persigehl; C Kobe; S Merkelbach-Bruse; J Franklin; H Backes; R Schnell; D Behringer; B Kaminsky; M Eichstaedt; C Stelzer; M Kinzig; F Sörgel; Y Tian; L Junge; AA Suleiman; S Frechen; D Rokitta; D Ouyang; U Fuhr; R Buettner; J Wolf,FDG-PET; KRAS mutation; Phase-I trial; non-small-cell lung cancer; pharmacodynamics; pharmacokinetics; solid tumors,,32436621,0.8774309754371643,2020,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
123,VA Thomas; JP Balthasar,anti-angiogenesis; drug–drug interaction; monoclonal antibodies; pharmacokinetics,,27029796,0.8773959279060364,2016,Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer.
124,H Richly; BF Henning; P Kupsch; K Passarge; M Grubert; RA Hilger; O Christensen; E Brendel; B Schwartz; M Ludwig; C Flashar; R Voigtmann; ME Scheulen; S Seeber; D Strumberg,,,16500908,0.8751437067985535,2006,Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
125,K Mross; S Steinbild; F Baas; M Reil; P Buss; S Mersmann; D Voliotis; B Schwartz; E Brendel,,,14692719,0.8750215172767639,2003,Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
126,A Foskett; C Manley; R Naramore; IK Gordon; BM Stewart; C Khanna,cancer; developmental therapeutics; sorafenib; tolerability study,,30050861,0.8688638210296631,2017,Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer.
127,F Marmé; C Gomez-Roca; K Graudenz; F Huang; J Lettieri; C Peña; ZJ Trnkova; J Eucker,Combination therapy; Dose; Inhibitors; Oncology; Phase 1; Safety; Tumors,,29468456,0.8676230311393738,2018,"Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors."
128,T Okusaka; T Otsuka; H Ueno; S Mitsunaga; R Sugimoto; K Muro; I Saito; Y Tadayasu; K Inoue; AB Loembé; M Ikeda,Hepatocellular carcinoma; Japanese; maximum tolerated dose; nintedanib; phase I,,27627050,0.860562264919281,2016,Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.
129,F Toffalorio; G Spitaleri; C Catania; L Dal Zotto; C Noberasco; A Delmonte; M Santarpia; F Vecchio; V Brunelli; C Rampinelli; M Barberis; C Fumagalli; M Zucchetti; M Zangarini; T Diena; R Danesi; F de Braud; T De Pas,,,24674875,0.855548620223999,2014,"Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets."
130,P Boudou-Rouquette; S Ropert; O Mir; R Coriat; B Billemont; M Tod; L Cabanes; N Franck; B Blanchet; F Goldwasser,,,22752067,0.8543714880943298,2012,Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
131,AL Harzstark; EJ Small; VK Weinberg; J Sun; CJ Ryan; AM Lin; L Fong; DR Brocks; JE Rosenberg,,,21387258,0.8534536361694336,2011,A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
132,TS Uldrick; PH Gonçalves; KM Wyvill; CJ Peer; W Bernstein; K Aleman; MN Polizzotto; D Venzon; SM Steinberg; V Marshall; D Whitby; RF Little; JJ Wright; MA Rudek; WD Figg; R Yarchoan,,,28341759,0.8412649035453796,2017,A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
133,S Afify; UR Rapp; P Högger,,,15282098,0.832491397857666,2004,Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
134,HL Ba; L Mbatchi; F Gattacceca; A Evrard; B Lacarelle; B Blanchet; J Ciccolini; S Salas,pharmacogenetics; pharmacokinetics; sorafenib; therapeutic drug monitoring; toxicity,,31967518,0.8316720128059387,2020,Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake.
135,M Shimada; H Okawa; T Maejima; T Yanagi; K Hisamichi; M Matsuura; K Akasaka; M Tsuchiya; Y Kondo; T Shimosegawa; M Mori; M Maekawa; H Suzuki; N Mano,,,24872323,0.8217915296554565,2014,A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
136,M Shimada; H Okawa; Y Kondo; T Maejima; Y Kataoka; K Hisamichi; M Maekawa; M Matsuura; Y Jin; M Mori; H Suzuki; T Shimosegawa; N Mano,,,26477611,0.8216115832328796,2015,Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
137,JB Aragon-Ching; L Jain; JL Gulley; PM Arlen; JJ Wright; SM Steinberg; D Draper; J Venitz; E Jones; CC Chen; WD Figg; WL Dahut,,,19154507,0.8168719410896301,2009,Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
138,B Escudier; M Gore,,,21679004,0.8150148391723633,2011,Axitinib for the management of metastatic renal cell carcinoma.
139,K Shinsako; T Mizuno; T Terada; J Watanabe; T Kamba; E Nakamura; O Ogawa; K Inui,,,20340037,0.8092238903045654,2010,Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
140,JH Park; MJ Baek; JY Lee; KT Kim; HJ Cho; DD Kim,Bioavailability; Microprecipitated bulk powder; Pharmacokinetics; Sorafenib; Ursodeoxycholic acid,,32946979,0.7998817563056946,2020,Preparation and characterization of sorafenib-loaded microprecipitated bulk powder for enhancing oral bioavailability.
141,S Faivre; A Santoro; RK Kelley; E Gane; CE Costentin; I Gueorguieva; C Smith; A Cleverly; MM Lahn; E Raymond; KA Benhadji; G Giannelli,TGF-β1; TGF-β1 receptor I inhibitor; alpha fetoprotein; galunisertib; hepatocellular carcinoma; liver cancer,,30963691,0.7980528473854065,2019,Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
142,PP Zarrinkar; RN Gunawardane; MD Cramer; MF Gardner; D Brigham; B Belli; MW Karaman; KW Pratz; G Pallares; Q Chao; KG Sprankle; HK Patel; M Levis; RC Armstrong; J James; SS Bhagwat,,,19654408,0.7942618727684021,2009,AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
143,D Luethi; S Durmus; AH Schinkel; JH Schellens; JH Beijnen; RW Sparidans,LC-MS/MS; bioanalytical assay; multikinase inhibitor; regorafenib,,24619951,0.7889190912246704,2014,Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
144,YH Choi; C Zhang; Z Liu; MJ Tu; AX Yu; AM Yu,,,33712506,0.7870925664901733,2021,A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism.
145,HY Lim; J Heo; HJ Choi; CY Lin; JH Yoon; C Hsu; KM Rau; RT Poon; W Yeo; JW Park; MH Tay; WS Hsieh; C Kappeler; P Rajagopalan; H Krissel; M Jeffers; CJ Yen; WY Tak,,,25294897,0.7854660749435425,2014,A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
146,X Ma; X Qin; X Shang; M Liu; X Wang,Drug-drug interactions; Knockout rat; Oatp1b2; Paclitaxel; Paclitaxel (PubChem CID: 36314); Sorafenib; Sorafenib (PubChem CID: 216239),,31437461,0.7825253009796143,2019,Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats.
147,DK Pawaskar; RM Straubinger; GJ Fetterly; BH Hylander; EA Repasky; WW Ma; WJ Jusko,,,23455451,0.7823118567466736,2013,Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
148,EQ Lee; J Kuhn; KR Lamborn; L Abrey; LM DeAngelis; F Lieberman; HI Robins; SM Chang; WK Yung; J Drappatz; MP Mehta; VA Levin; K Aldape; JE Dancey; JJ Wright; MD Prados; TF Cloughesy; MR Gilbert; PY Wen,,,23099651,0.7810147404670715,2012,Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
149,S Naito; H Sakai; K Hashine; Y Tomita; N Shinohara; M Fujisawa; M Eto; S Ozono; H Akaza,S-1; metastatic renal cell carcinoma; sorafenib,,26117830,0.7791815400123596,2015,Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
150,DS Hong; SM Sebti; RA Newman; MA Blaskovich; L Ye; RF Gagel; S Moulder; JJ Wheler; A Naing; NM Tannir; CS Ng; SI Sherman; AK El Naggar; R Khan; J Trent; JJ Wright; R Kurzrock,,,19903778,0.7781326770782471,2009,Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
151,C Fucile; S Marenco; M Bazzica; ML Zuccoli; F Lantieri; L Robbiano; V Marini; P Di Gion; G Pieri; P Stura; A Martelli; V Savarino; F Mattioli; A Picciotto,,,25429830,0.7686805129051208,2015,Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
152,Y Yamada; N Kiyota; N Fuse; K Kato; H Minami; K Hashizume; Y Kuroki; Y Ito; A Ohtsu,,,23532594,0.7608710527420044,2014,A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
153,A Karbownik; M Miedziaszczyk; T Grabowski; J Stanisławiak-Rudowicz; R Jaźwiec; A Wolc; E Grześkowiak; E Szałek,Drug-drug interaction; Pharmacokinetics; Sorafenib; Sorafenib N-oxide; Tapentadol; Tapentadol glucuronide,,32712531,0.7599851489067078,2020,In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol.
154,GM Beasley; AP Coleman; A Raymond; G Sanders; MA Selim; BL Peterson; MS Brady; MA Davies; C Augustine; DS Tyler,,,22549288,0.7513847947120667,2012,A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
155,X Sheng; T Huang; J Qin; Q Li; W Wang; L Deng; A Dong,liver cancer; nanoparticle; sorafenib; target,,29113262,0.7470621466636658,2017,"Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticles in vivo."
156,NS Azad; JB Aragon-Ching; WL Dahut; M Gutierrez; WD Figg; L Jain; SM Steinberg; ML Turner; EC Kohn; HH Kong,,,19228742,0.746148943901062,2009,Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
157,M Fukudo; T Ito; T Mizuno; K Shinsako; E Hatano; S Uemoto; T Kamba; T Yamasaki; O Ogawa; H Seno; T Chiba; K Matsubara,,,24135988,0.744728684425354,2014,Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
158,JM Meyer; KS Perlewitz; JB Hayden; YC Doung; AY Hung; JT Vetto; RF Pommier; A Mansoor; BR Beckett; A Tudorica; M Mori; ML Holtorf; A Afzal; WJ Woodward; ET Rodler; RL Jones; W Huang; CW Ryan,,,24132922,0.7429410815238953,2013,Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
159,RW Sparidans; S Durmus; AH Schinkel; JH Schellens; JH Beijnen,,,22386128,0.7416312098503113,2012,Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
160,HT Abdel-Mohsen; AS Girgis; AEE Mahmoud; MM Ali; HI El Diwani,2-thiopyrimidines; ADME; VEGFR-2 inhibitors; angiogenesis; hepatocellular carcinoma,,31463965,0.7335137128829956,2019,"New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation."
161,M Tandia; A Mhiri; B Paule; R Saffroy; V Cailliez; G Noé; R Farinotti; L Bonhomme-Faivre,Brest cancer resistance protein (ABCG2); Drug monitoring; Hepatocellular carcinoma (HCC); P-glycoprotein (ABCB1); Single nucleotide polymorphism (SNP); Sorafenib,,28289864,0.7321898341178894,2017,Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
162,S Noda; D Hira; R Osaki; T Fujimoto; H Iida; S Tanaka-Mizuno; A Andoh; M Tani; Y Ikeda; SY Morita; T Terada,Hepatocellular carcinoma; Personalized pharmacotherapy; Pharmacokinetics; Sorafenib,,32588123,0.7300717830657959,2020,Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.
163,S Bhatia; B Curti; MS Ernstoff; M Gordon; EI Heath; WH Miller; I Puzanov; DI Quinn; TW Flaig; P VanVeldhuizen; K Byrnes-Blake; JA Freeman; R Bittner; N Hunder; S Souza; JA Thompson,Cytokine; Durable response; Immunotherapy; Interleukin-21; Renal cell carcinoma (RCC); Sorafenib; Targeted therapy; Tyrosine kinase inhibitors (TKI); VEGF,,24829759,0.729890763759613,2014,Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.
164,MS Kim,,,23336707,0.7285408973693848,2013,Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs.
165,EI Zimmerman; JL Roberts; L Li; D Finkelstein; A Gibson; AS Chaudhry; EG Schuetz; JE Rubnitz; H Inaba; SD Baker,,,22927483,0.7162328362464905,2012,Ontogeny and sorafenib metabolism.
166,CJ Yen; TY Kim; YH Feng; Y Chao; DY Lin; BY Ryoo; DC Huang; D Schnell; J Hocke; AB Loembé; AL Cheng,Advanced hepatocellular carcinoma; Angiokinase inhibitor; Dose-limiting toxicity; Maximum tolerated dose; Nintedanib; Sorafenib,,29888206,0.7123367786407471,2018,"A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma."
167,D Strumberg; JW Clark; A Awada; MJ Moore; H Richly; A Hendlisz; HW Hirte; JP Eder; HJ Lenz; B Schwartz,,,17470685,0.7115866541862488,2007,"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors."
168,P Di Gion; F Kanefendt; A Lindauer; M Scheffler; O Doroshyenko; U Fuhr; J Wolf; U Jaehde,,,21827214,0.7091594338417053,2011,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles."
169,K Asari; H Takahashi,,,33191909,0.7086095213890076,2021,Proposal of a prediction model describing the metabolic interaction between warfarin and sorafenib using a population pharmacokinetic approach.
170,S Hu; H Niu; H Inaba; S Orwick; C Rose; JC Panetta; S Yang; S Pounds; Y Fan; C Calabrese; JE Rehg; D Campana; JE Rubnitz; SD Baker,,,21487100,0.7046298384666443,2011,Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
171,WM Eldehna; AM El Kerdawy; GH Al-Ansary; ST Al-Rashood; MM Ali; AE Mahmoud,FGFR-1 and PDGFR-b; Indolinone; Molecular modeling; Multikinase inhibitor; Synthesis; VEGFR-2,,30503942,0.7039402723312378,2019,"Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides."
172,K Dredge; E Hammond; P Handley; TJ Gonda; MT Smith; C Vincent; R Brandt; V Ferro; I Bytheway,,,21285983,0.6934319734573364,2011,"PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models."
173,D Strumberg; D Voliotis; JG Moeller; RA Hilger; H Richly; S Kredtke; C Beling; ME Scheulen; S Seeber,,,12503822,0.6858155727386475,2002,Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
174,X Wang; X Zhang; X Huang; Y Li; M Wu; J Liu,CYP450; Caco-2 cells; P-gp; drug–drug interaction; oral absorption; sorafenib,,26582036,0.677577555179596,2016,The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4.
175,JD Wu; YJ Cui; YG Zhou; LQ Tang; CM Zhang; ZP Liu,Hepatocellular carcinoma; Liver microsome stability; Multidrug-resistance; Pharmacokinetics; Tubulin polymerization inhibitor,,30887253,0.672903299331665,2020,Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
176,S Bae; R D'Cunha; J Shao; G An,"5,7-Dimethoxyflavone; Breast cancer resistance protein; Drug-drug interactions; Pharmacokinetics; Tyrosine kinase inhibitors",,29425861,0.6704403758049011,2018,"Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice."
177,WJ Heinz; K Kahle; A Helle-Beyersdorf; D Schirmer; U Lenker; D Keller; P Langmann; H Klinker,,,20927524,0.6621999144554138,2011,High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
178,GM Kim; MD Kim; do Y Kim; SH Kim; JY Won; SI Park; do Y Lee; W Shin; M Shin,,,27179404,0.6582418084144592,2016,Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
179,J James; B Ruggeri; RC Armstrong; MW Rowbottom; S Jones-Bolin; RN Gunawardane; P Dobrzanski; MF Gardner; H Zhao; MD Cramer; K Hunter; RR Nepomuceno; M Cheng; D Gitnick; M Yazdanian; DE Insko; MA Ator; JL Apuy; R Faraoni; BD Dorsey; M Williams; SS Bhagwat; MW Holladay,,,22319199,0.65501469373703,2012,CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
180,EG Chiorean; SM Perkins; RM Strother; A Younger; JM Funke; SG Shahda; NM Hahn; K Sandrasegaran; DR Jones; TC Skaar; BP Schneider; CJ Sweeney; DE Matei,,,32847973,0.6516661643981934,2020,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors."
181,Y Chen; JX Li; N Shu; SJ Zheng; M Ma; ZB Zhao; ZT Cao; Q Zhou; JZ Du; J Wang,,,33459733,0.6506817936897278,2021,A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy.
182,S Hu; Z Chen; R Franke; S Orwick; M Zhao; MA Rudek; A Sparreboom; SD Baker,,,19773380,0.6502768397331238,2009,Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
183,LH Mammatas; AS Zandvliet; M Rovithi; RJ Honeywell; EL Swart; GJ Peters; CW Menke-van der Houven van Oordt; HMW Verheul,Cola; Drug monitoring; High dose; Phase I clinical trial; Pulsatile; Sorafenib,,32274565,0.6440260410308838,2020,"Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study."
184,Y Liu; J Yang; X Wang; J Liu; Z Wang; H Liu; L Chen,D-α-tocopherol succinate; Sorafenib; drug delivery; poly (acryic acid); redox responsive nanomicelles,,27632696,0.6436432003974915,2016,In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate.
185,SM Federico; KJ Caldwell; MB McCarville; VM Daryani; CF Stewart; S Mao; J Wu; AM Davidoff; VM Santana; WL Furman; AS Pappo; F Navid,Bevacizumab; Cyclophosphamide; Paediatric; Phase I; Solid tumours; Sorafenib,,32325418,0.6367388963699341,2020,"Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours."
186,AN Chatziioannou; AP Siskos; D Loxas; N Kavatzas; G Agrogiannis; D Fokas; K Malagari; NG Kostomitsopoulos; O Tsigkou; C Tamvakopoulos,ALT; AST; AcCN; GGT; HCC; LC-ESI-MS/MS; LC-MS/MS; acetonitrile; alanine aminotransferase; aspartate aminotransferase; hepatocellular carcinoma; liquid chromatography electrospray ionization mass spectrometry; liquid chromatography tandem mass spectrometry; γ-glutamyltransferase,,24060438,0.6347151398658752,2013,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
187,AG Duffy; C Ma; SV Ulahannan; OE Rahma; O Makarova-Rusher; L Cao; Y Yu; DE Kleiner; J Trepel; MJ Lee; Y Tomita; SM Steinberg; T Heller; B Turkbey; PL Choyke; CJ Peer; WD Figg; BJ Wood; TF Greten,,,28465443,0.62330162525177,2017,Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
188,M El-Madani; O Colomban; M Tod; D Maillet; J Peron; C Rodriguez-Lafrasse; OA Badary; PJ Valette; T Lefort; P Cassier; SM El-Shenawy; E El-Demerdash; J Hommel-Fontaine; J Guitton; MC Gagnieu; BM Ibrahim; C Barrois; G Freyer; B You,Phase I; administration and dosage; adverse events; angiogenesis inhibitors; everolimus; maximum tolerated dose; modeling; pharmacokinetics; solid tumor; sorafenib; targeted therapy,,28076966,0.6157126426696777,2017,"EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib."
189,HH Wong; T Eisen,,,23773100,0.6074692010879517,2013,Tivozanib for the treatment of metastatic renal cancer.
190,NS Azad; EM Posadas; VE Kwitkowski; SM Steinberg; L Jain; CM Annunziata; L Minasian; G Sarosy; HL Kotz; A Premkumar; L Cao; D McNally; C Chow; HX Chen; JJ Wright; WD Figg; EC Kohn,,,18669456,0.5985174775123596,2008,Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
191,JL Jilek; MJ Tu; C Zhang; AM Yu,,,33051247,0.597095251083374,2020,Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
192,A Kim; BC Widemann; M Krailo; N Jayaprakash; E Fox; B Weigel; SM Blaney,pediatrics; solid tumors; sorafenib,,26207356,0.5889840126037598,2015,Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
193,V Escudero-Ortiz; JJ Pérez-Ruixo; B Valenzuela,,,24365980,0.5757383704185486,2014,Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
194,H Chen; J Kuhn; KR Lamborn; LE Abrey; LM DeAngelis; F Lieberman; HI Robins; SM Chang; WKA Yung; J Drappatz; MP Mehta; VA Levin; K Aldape; JE Dancey; JJ Wright; MD Prados; TF Cloughesy; PY Wen; MR Gilbert,erlotinib; glioblastoma; molecular therapy; novel trial design; sorafenib,,33235994,0.5734092593193054,2020,Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
195,DK Pawaskar; RM Straubinger; GJ Fetterly; BH Hylander; EA Repasky; WW Ma; WJ Jusko,,,23455452,0.5606333017349243,2013,Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
196,H Mai; J Huang; Y Zhang; N Qu; H Qu; GH Mei; J Liu; X Xu; L Chen,pharmacokinetics and HPLC-MS/MS; plasma concentration; renal cell cancer; sorafenib,,28404979,0.5486603379249573,2017,In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
197,C Phan; Z Zheng; J Wang; Q Wang; X Hu; G Tang; H Bai,,,31509117,0.5450800657272339,2019,Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
198,JS Lind; AM Dingemans; HJ Groen; FB Thunnissen; O Bekers; DA Heideman; RJ Honeywell; E Giovannetti; GJ Peters; PE Postmus; RJ van Suylen; EF Smit,,,20395213,0.5398972034454346,2010,A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
199,B Wu; A Li; Y Zhang; X Liu; S Zhou; H Gan; S Cai; Y Liang; X Tang,BEZ235; Hepatocellular carcinoma; PI3K/mTOR; apoptosis; nanoparticles; polycaprolactone; sorafenib,,32056461,0.5273013114929199,2020,Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
200,EG Chiorean; BP Schneider; FM Akisik; SM Perkins; S Anderson; CS Johnson; J DeWitt; P Helft; R Clark; EL Johnston; AJ Spittler; J Deluca; G Bu; S Shahda; PJ Loehrer; K Sandrasegaran; HR Cardenes,,,24726286,0.5269925594329834,2014,Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
201,S Yang; B Zhang; X Gong; T Wang; Y Liu; N Zhang,HCC; antitumor effect; distribution; lipid-based nanosuspensions; sorafenib,,27307733,0.5238920450210571,2016,"In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer."
